menu
    • menu
    [{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Farudodstat","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ASLAN Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ K2 HealthVentures"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Farudodstat","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Farudodstat","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Farudodstat

    Menu

    Farudodstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata

                            Details : ASLAN003 (farudodstat) is a potent oral DHODH inhibitor that suppresses immune cell proliferation and IFNγ secretion by blocking de novo production of pyrimidines required for DNA replication. It is being developed for alopecia areata.

                            Brand Name : ASLAN003

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 18, 2023

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential ...

                            Details : ASLAN003 (farudodstat) is a potent oral DHODH inhibitor that suppresses immune cell proliferation and IFNγ secretion by blocking de novo production of pyrimidines required for DNA replication. It is being developed for alopecia areata.

                            Brand Name : ASLAN003

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 28, 2023

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : K2 HealthVentures

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures

                            Details : The company intends to use the proceeds of the loan facility to advance the clinical development of ASLAN003, a promising candidate for the potential treatment of autoimmune gastrointestinal and skin diseases, especially inflammatory bowel disease as wel...

                            Brand Name : ASLAN003

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 13, 2021

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : K2 HealthVentures

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Study Suggests ASLAN Pharmaceutical's ASLAN003 Has the Potential to Be the Best-In-Class DHODH Inhibitor

                            Details : New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors.

                            Brand Name : ASLAN003

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 26, 2021

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ASLAN Pharmaceuticals

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

                            Details : ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide.

                            Brand Name : ASLAN003

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 16, 2020

                            Lead Product(s) : Farudodstat

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth